GO:0031559 oxidosqualene cyclase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031559 (oxidosqualene cyclase activity) is a molecular_function defined as the catalysis of the cyclization of (S)-2,3-epoxysqualene to form a triterpene.
• This single enzymatic step is the branch point of sterol and triterpenoid biosynthesis, converting the linear 30-carbon substrate into the cyclic skeletons of cholesterol, lanosterol, plant sterols, and ginsenosides.
• Lanosterol synthase (LSS) is the principal mammalian oxidosqualene cyclase, and its loss of function reduces malignant phenotypes in HepG2 cells by deactivating Src/MAPK signaling.
• De novo cholesterol synthesis, which depends on oxidosqualene cyclase activity, supports mTORC1 activity and is linked to ATR signaling.
• Oxidosqualene cyclase inhibitors such as bis-azasqualenes and isoquinoline derivatives show antifungal and cholesterol-lowering potential.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of oxidosqualene cyclase genes in sterol and triterpenoid pathways.
Description
Oxidosqualene cyclase activity (GO:0031559) is a molecular_function that catalyzes the cyclization of (S)-2,3-epoxysqualene to form a triterpene. This reaction is one of the most remarkable transformations in natural product biosynthesis, converting a linear 30-carbon epoxide into the polycyclic scaffolds that underlie sterols, triterpenoids, and saponins. Because the same substrate can be folded into dozens of distinct ring systems, oxidosqualene cyclases are regarded as key diversification enzymes in both primary and specialized metabolism. In mammals, lanosterol synthase carries out this activity to initiate the sterol branch of the mevalonate pathway, whereas plants and fungi use multiple oxidosqualene cyclases to generate triterpenoid diversity. The reaction is therefore central to membrane biogenesis, hormone synthesis, and the production of pharmacologically active compounds such as ginsenosides. Researchers study GO:0031559 to understand how a single cyclization event controls carbon flux into cholesterol and triterpenoids, and to identify drug targets for cancer, fungal infections, and metabolic disease. Because the enzyme sits at a metabolic branch point, its activity is sensitive to substrate supply, product demand, and signaling inputs such as mTORC1 and ATR.
oxidosqualene cyclase activity At A Glance
| GO ID | GO:0031559 |
|---|---|
| GO term | oxidosqualene cyclase activity |
| Ontology | molecular_function |
| Synonym | 2,3-oxidosqualene cyclase activity |
| Definition | Catalysis of the cyclization of (S)-2,3-epoxysqualene to form a triterpene |
| Major function | Cyclization of (S)-2,3-epoxysqualene into cyclic triterpene scaffolds |
| Substrate | (S)-2,3-epoxysqualene |
| Product class | Triterpenes (e.g., lanosterol, cycloartenol, ginsenoside precursors) |
| Pathway context | Mevalonate/sterol and triterpenoid biosynthesis |
| Representative enzyme | Lanosterol synthase (LSS) in mammals |
What Is GO:0031559?
In the Gene Ontology, GO:0031559 (oxidosqualene cyclase activity) is defined as the catalysis of the cyclization of (S)-2,3-epoxysqualene to form a triterpene. The synonym 2,3-oxidosqualene cyclase activity reflects the same enzymatic step. Functionally, the term describes an enzyme that binds the linear epoxide (S)-2,3-epoxysqualene and promotes an intramolecular ring closure, producing a cyclic triterpene product such as lanosterol, cycloartenol, or a plant triterpenoid. This activity is distinct from upstream squalene epoxidation and downstream sterol modifications, and it represents the first committed cyclization step in the sterol/triterpenoid branch of the mevalonate pathway.
Why Is oxidosqualene cyclase activity Important in Cell Biology?
Oxidosqualene cyclase activity is important because it controls the first committed cyclization step that separates sterol biosynthesis from other branches of the mevalonate pathway. In mammals, this activity is required for lanosterol and cholesterol production, which in turn supports membrane integrity, steroid hormone synthesis, and mTORC1 signaling. In plants, oxidosqualene cyclases generate the triterpenoid scaffolds of ginsenosides and other bioactive saponins, making them central to medicinal plant biotechnology. In fungi, the enzyme is a validated antifungal target, and inhibitors such as bis-azasqualenes exploit this dependency. In cancer, loss of lanosterol synthase function decreases malignant phenotypes in HepG2 cells by deactivating Src/MAPK signaling, highlighting the therapeutic relevance of this activity. Finally, environmental exposures such as PFAS can dysregulate cholesterol accumulation and inflammatory responses in macrophages, implicating sterol pathway enzymes in immunometabolism.
• Defines the branch point between sterol and triterpenoid biosynthesis.
• Required for lanosterol and cholesterol production in mammals.
• Supports mTORC1 activity through de novo cholesterol synthesis.
• Generates triterpenoid scaffolds of ginsenosides in Panax species.
• Provides a validated target for antifungal drug development.
• Isoquinoline-derived inhibitors of mammalian oxidosqualene cyclase have been characterized.
• Lanosterol synthase loss of function reduces malignant phenotypes in HepG2 cells.
• Links sterol metabolism to inflammatory responses in macrophages exposed to PFAS.
• Enables metabolic engineering of plant triterpenoid production.
• Serves as a model for understanding enzyme-catalyzed polycyclization.
Molecular Mechanism of oxidosqualene cyclase activity
Substrate binding and pre-folding
In simple terms: The enzyme grabs a long, floppy molecule and folds it into the right shape before cutting and joining it into rings.
Oxidosqualene cyclase activity begins with binding of the linear substrate (S)-2,3-epoxysqualene in an extended conformation within the enzyme active site. The enzyme templates the substrate into a specific pre-folded conformation that positions the epoxide and the terminal double bonds for a concerted cyclization cascade. This substrate pre-organization is a hallmark of triterpene synthases and explains how a single substrate can yield diverse ring skeletons depending on the enzyme.
Epoxide protonation and ring closure
In simple terms: A proton starts the reaction, causing the molecule to curl up and form rings.
The catalytic cycle is initiated by protonation of the epoxide oxygen of (S)-2,3-epoxysqualene, generating a carbocation that triggers a cascade of intramolecular ring closures. This cationic cascade converts the linear substrate into a cyclic triterpene, with the specific ring system determined by the enzyme active-site architecture. The reaction is a classic example of enzymatic polycyclization and is the defining catalytic event of GO:0031559.
Product release and triterpene diversity
In simple terms: The finished ring molecule is released, and different enzymes make different ring shapes.
Following cyclization, the triterpene product is released from the active site. In mammals, lanosterol synthase produces lanosterol, the precursor of cholesterol. In plants, multiple oxidosqualene cyclases generate diverse triterpenoid skeletons that serve as precursors for ginsenosides and other saponins. This product diversity is a direct consequence of variations in the cyclization mechanism and active-site residues.
Cofactors and catalytic requirements
In simple terms: The enzyme does not need special helper molecules; it uses its own acidic residues to start the reaction.
Oxidosqualene cyclase activity does not require metal cofactors or external energy sources; instead, conserved acidic residues in the active site protonate the epoxide to initiate catalysis. The reaction is therefore an example of acid-base catalysis coupled to substrate pre-organization. This simplicity makes the enzyme amenable to inhibitor design, as exemplified by isoquinoline-derived inhibitors of mammalian 2,3-oxidosqualene cyclase.
Regulation by pathway demand and signaling
In simple terms: The cell adjusts how much of this enzyme activity it needs based on cholesterol demand and growth signals.
Oxidosqualene cyclase activity is embedded in the mevalonate pathway and is regulated by sterol demand and signaling inputs. ATR promotes mTORC1 activity via de novo cholesterol synthesis, linking growth signaling to sterol pathway flux. In cancer cells, loss of lanosterol synthase function decreases malignant phenotypes by deactivating Src/MAPK signaling, indicating that this activity can influence oncogenic pathways. In macrophages, PFAS exposure enhances cholesterol accumulation and dysregulates inflammatory responses, further connecting sterol pathway activity to immune regulation.
Key Genes Involved in GO:0031559 oxidosqualene cyclase activity
The following genes and proteins are directly or functionally associated with oxidosqualene cyclase activity (GO:0031559) and its downstream sterol/triterpenoid pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LSS | Lanosterol synthase; principal mammalian oxidosqualene cyclase | Cancer, cholesterol synthesis, Src/MAPK signaling |
| SQLE | Squalene epoxidase; produces (S)-2,3-epoxysqualene upstream of GO:0031559 | Sterol pathway flux, antifungal target |
| HMGCR | Rate-limiting enzyme of mevalonate pathway upstream of oxidosqualene cyclase | Cholesterol synthesis, mTORC1 regulation |
| CYP51A1 | Lanosterol 14-alpha demethylase downstream of lanosterol synthase | Sterol biosynthesis, antifungal target |
| DHCR7 | 7-dehydrocholesterol reductase; terminal cholesterol synthesis enzyme | Cholesterol metabolism, developmental disorders |
| DHCR24 | 24-dehydrocholesterol reductase; cholesterol synthesis | Sterol metabolism, neuroprotection |
| ATR | Kinase that promotes mTORC1 activity via de novo cholesterol synthesis | Growth signaling, cholesterol pathway |
| MTOR | mTORC1 kinase; responds to cholesterol synthesis | Cell growth, metabolism |
| SRC | Proto-oncogene kinase deactivated upon LSS loss | Cancer signaling |
| MAPK1 | MAPK pathway kinase downstream of Src | Cancer proliferation |
| MAPK3 | MAPK pathway kinase downstream of Src | Cancer proliferation |
| CYP716A | Plant cytochrome P450 oxidizing triterpene scaffolds | Ginsenoside biosynthesis |
| UGT | UDP-glycosyltransferase decorating triterpenoids | Ginsenoside biosynthesis |
| OSC | Plant oxidosqualene cyclase family | Triterpenoid diversity |
| CAS | Cycloartenol synthase; plant oxidosqualene cyclase | Plant sterol biosynthesis |
| LAS | Lanosterol synthase in plants/fungi | Triterpenoid biosynthesis |
| ERG7 | Fungal lanosterol synthase | Antifungal target |
How Is oxidosqualene cyclase activity Regulated?
Oxidosqualene cyclase activity is regulated at multiple levels. Transcriptional control of sterol pathway genes responds to sterol demand, while signaling inputs such as ATR promote mTORC1 activity via de novo cholesterol synthesis, indirectly influencing flux through oxidosqualene cyclase. In cancer cells, loss of lanosterol synthase function decreases malignant phenotypes by deactivating Src/MAPK signaling, indicating that this activity is integrated with oncogenic kinase cascades. In macrophages, PFAS exposure enhances cholesterol accumulation and dysregulates inflammatory responses, linking environmental factors to sterol pathway regulation. Inhibitors such as bis-azasqualenes and isoquinoline derivatives can directly block oxidosqualene cyclase activity, providing pharmacological control.
oxidosqualene cyclase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LSS | Hepatocellular carcinoma; Src/MAPK signaling | LSS knockout HepG2 cells |
| LSS | Cholesterol synthesis disorders | LSS point-mutation knock-in cell lines |
| SQLE | Sterol pathway dysregulation | SQLE overexpression models |
| ERG7 | Fungal infections | Antifungal susceptibility assays with bis-azasqualenes |
| OSC | Triterpenoid biosynthesis | Plant oxidosqualene cyclase overexpression in heterologous systems |
Cancer and oncogenic signaling
Lanosterol synthase loss of function decreases the malignant phenotypes of HepG2 cells by deactivating the Src/MAPK signaling pathway, demonstrating that oxidosqualene cyclase activity can support cancer cell proliferation and survival. This positions the enzyme as a potential target in hepatocellular carcinoma and other cancers dependent on sterol pathway flux.
Metabolic and inflammatory disease
Per- and polyfluoroalkyl substances (PFAS) enhance cholesterol accumulation and dysregulate inflammatory responses in macrophages, implicating sterol pathway enzymes, including oxidosqualene cyclase, in immunometabolic disease. Because de novo cholesterol synthesis supports mTORC1 activity, dysregulation of this pathway may contribute to metabolic disorders.
Fungal infections
Oxidosqualene cyclase is a validated antifungal target, and bis-azasqualene inhibitors of the enzyme display antifungal activity. This makes GO:0031559 a relevant molecular function for antifungal drug discovery.
Plant triterpenoid pharmacology
Plant oxidosqualene cyclases generate triterpenoid scaffolds that are further modified into ginsenosides and other bioactive saponins with pharmacological activities. Understanding these enzymes supports metabolic engineering of medicinal plants and biotechnological production of triterpenoids.
From oxidosqualene cyclase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LSS reduce cancer cell proliferation? | LSS knockout in HepG2 cells |
| Does a specific LSS mutation alter cyclization activity? | Point-mutation knock-in of LSS |
| Can a tagged oxidosqualene cyclase be tracked in live cells? | Tagged knock-in of LSS or plant OSC |
| Does overexpression of a plant OSC increase triterpenoid yield? | OSC overexpression in plant or microbial hosts |
| Does oxidosqualene cyclase inhibition affect fungal growth? | Fungal strains treated with bis-azasqualenes |
| Does cholesterol synthesis regulate mTORC1? | ATR or LSS perturbation with mTORC1 readouts |
How to Study the oxidosqualene cyclase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic cyclization assay | Conversion of (S)-2,3-epoxysqualene to triterpene | Mechanistic and inhibitor studies |
| LC-MS sterol profiling | Lanosterol and cholesterol levels | Pathway flux analysis |
| RNA-seq | Transcriptional changes in sterol/triterpenoid genes | Plant and mammalian pathway studies |
| CRISPR knockout | Loss-of-function phenotypes | Cancer and metabolic models |
| Overexpression | Gain-of-function effects on triterpenoid yield | Plant biotechnology |
| Western blot | Src/MAPK and mTORC1 signaling | Cancer and growth signaling |
| Antifungal susceptibility testing | Fungal growth inhibition | Drug discovery |
| Metabolomics | Global triterpenoid and sterol changes | Pathway discovery |
Enzymatic activity assays
Oxidosqualene cyclase activity can be measured using substrate conversion assays with (S)-2,3-epoxysqualene and product detection by chromatography or mass spectrometry. Inhibitor studies with isoquinoline derivatives or bis-azasqualenes provide kinetic and mechanistic insight.
Genetic perturbation and phenotyping
CRISPR knockout of LSS or plant OSC genes followed by proliferation, signaling, and sterol profiling reveals the cellular consequences of losing oxidosqualene cyclase activity. Overexpression models complement loss-of-function studies by testing sufficiency.
Transcriptomics and metabolomics
RNA-seq and metabolomics can map pathway flux changes when oxidosqualene cyclase activity is altered, linking gene expression to triterpene and sterol output. These approaches are especially useful in medicinal plant research on ginsenoside biosynthesis.
Signaling pathway analysis
Western blotting and phospho-protein analysis can assess Src/MAPK and mTORC1 signaling after perturbation of oxidosqualene cyclase activity. Such experiments connect the enzyme to oncogenic and growth-regulatory networks.
How CRISPR Can Be Used to Study GO:0031559 oxidosqualene cyclase activity
Knockout
CRISPR knockout of LSS or plant OSC genes eliminates oxidosqualene cyclase activity, enabling assessment of downstream effects on sterol synthesis, cancer cell phenotypes, and triterpenoid production. Knockout HepG2 cells have been used to show that LSS loss decreases malignant phenotypes via Src/MAPK deactivation.
Point Mutation
Point-mutation knock-in can be used to test specific active-site residues required for cyclization, distinguishing catalytic residues from structural ones. Such models help validate mechanistic hypotheses derived from enzyme structure-function studies.
Knock-in
Tagged knock-in of oxidosqualene cyclase genes allows localization and interaction studies in native chromatin context. This is valuable for tracking enzyme distribution in plant and mammalian cells.
Overexpression
Overexpression of plant or mammalian oxidosqualene cyclases can increase flux toward triterpenoids or sterols, supporting metabolic engineering and drug production. Overexpression models also test whether the enzyme is rate-limiting in a given pathway.
How EDITGENE Supports oxidosqualene cyclase activity Research
Researchers studying oxidosqualene cyclase activity-related genes often need to determine whether a candidate gene is causally involved in sterol or triterpenoid biosynthesis, cancer phenotypes, or metabolic regulation. Rigorous causal inference requires precise genetic models that isolate the enzyme's contribution from compensatory pathway changes.
Contact EDITGENE today to design your custom CRISPR model for oxidosqualene cyclase activity research.
Frequently Asked Questions About oxidosqualene cyclase activity
What is oxidosqualene cyclase activity?
Oxidosqualene cyclase activity (GO:0031559) is a molecular function that catalyzes the cyclization of (S)-2,3-epoxysqualene to form a triterpene.
What is the GO ID for oxidosqualene cyclase activity?
The Gene Ontology ID for oxidosqualene cyclase activity is GO:0031559.
What genes are involved in oxidosqualene cyclase activity?
Key genes include LSS (lanosterol synthase) in mammals, ERG7 in fungi, and plant OSC family genes such as CAS and LAS.
What is the substrate of oxidosqualene cyclase?
The substrate is (S)-2,3-epoxysqualene, a linear 30-carbon epoxide.
What products are formed by oxidosqualene cyclase activity?
Products are triterpenes such as lanosterol, cycloartenol, and plant triterpenoid scaffolds used for ginsenoside biosynthesis.
Why is oxidosqualene cyclase important in cancer?
Lanosterol synthase loss of function decreases malignant phenotypes in HepG2 cells by deactivating Src/MAPK signaling.
How is oxidosqualene cyclase activity linked to cholesterol synthesis?
It is the first committed cyclization step in the sterol branch of the mevalonate pathway, producing lanosterol for cholesterol synthesis.
Are there inhibitors of oxidosqualene cyclase?
Yes, bis-azasqualenes and isoquinoline-derived compounds inhibit oxidosqualene cyclase and show antifungal or cholesterol-lowering potential.
How can I study oxidosqualene cyclase activity in the lab?
Enzymatic assays, CRISPR knockout, overexpression, RNA-seq, metabolomics, and signaling analysis are commonly used.
Does oxidosqualene cyclase activity affect mTORC1 signaling?
ATR promotes mTORC1 activity via de novo cholesterol synthesis, linking sterol pathway flux to mTORC1.
Conclusion
Oxidosqualene cyclase activity (GO:0031559) is a pivotal molecular function that converts (S)-2,3-epoxysqualene into cyclic triterpenes, controlling flux into sterols and triterpenoids. Its roles span cholesterol synthesis, mTORC1 signaling, cancer cell phenotypes, antifungal drug action, and plant ginsenoside biosynthesis. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide the causal evidence needed to translate this activity into therapeutic and biotechnological applications. Continued research on oxidosqualene cyclases will clarify how a single cyclization event shapes diverse metabolic and disease outcomes.
References
- 1. Hou M et al.. 2021. Ginsenosides in Panax genus and their biosynthesis.. Acta Pharm Sin B 11(7):1813-1834 PMID: 34386322
- 2. Sun X et al.. 2023. Lanosterol synthase loss of function decreases the malignant phenotypes of HepG2 cells by deactivating the Src/MAPK signaling pathway.. Oncol Lett 26(1):295 PMID: 37274468
- 3. Xiang L et al.. 2026. Biosynthesis and Biotransformation of Plant Triterpenoids: Current Advances and Future Perspectives.. Adv Biochem Eng Biotechnol PMID: 42720748
- 4. Connolly JC et al.. 2025. Per- and Polyfluoroalkyl Substances (PFAS) Enhance Cholesterol Accumulation and Dysregulate Inflammatory Responses in Macrophages.. Cardiovasc Toxicol 25(10):1455-1470 PMID: 40728694
- 5. Voyron S et al.. 2010. Antifungal activity of bis-azasqualenes, inhibitors of oxidosqualene cyclase.. Mycoses 53(6):481-7 PMID: 19549106
- 6. Tangudu NK et al.. 2025. ATR promotes mTORC1 activity via de novo cholesterol synthesis.. EMBO Rep 26(14):3574-3593 PMID: 40514450
- 7. Abe I. 2007. Enzymatic synthesis of cyclic triterpenes.. Nat Prod Rep 24(6):1311-31 PMID: 18033581
- 8. Binet J et al.. 2002. Structure activity relationships of new inhibitors of mammalian 2,3-oxidosqualene cyclase designed from isoquinoline derivatives.. Chem Pharm Bull (Tokyo) 50(3):316-29 PMID: 11911193
